A new drug to restore function following spinal cord injury.
Novoron Bioscience, Inc.
Novoron, a private biotechnology company, was founded in February 2013 to develop pharmaceutical therapies for nerve regeneration of the central nervous system (CNS). To date, we have established our intellectual property portfolio and received multiple Phase-1 grants from the National Institutes of Health (NIH) in order to pursue our mission:
To develop our groundbreaking discovery into therapies promoting recovery for patients suffering from conditions related to a damaged CNS.
Novoron is developing novel therapeutic approaches to address disorders of the central nervous system (CNS). Our technology foundation is based on having identified a receptor capable of mediating regenerative inhibition that takes place in the CNS, such as occurs in spinal cord injury. Thus, Novoron has been working to exploit this target for the regeneration of spinal cord neurons after injury. Additionally, candidate biologic agents in our pipeline have the capacity to block an important cell-signal involved in various disease pathologies known as, "RhoA." Through targeting RhoA activation, we have expanded our exploratory efforts to treatments for glaucoma and multiple sclerosis.